Viridian Therapeutics, Inc.\DE (VRDN) insider trading
Every open-market stock purchase and sale by Viridian Therapeutics, Inc.\DE executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Jennifer Tousignant (C-suite exec) sold $348K in the last 90 days.
- Last insider buy: Fairmount Funds Management LLC (10% owner), $20M, 5 months ago.
Last 12 months: insiders bought $30M (2 buys) and sold $419K (2 sales). Last close $22.82 on Oct 22, 2026.
Recent VRDN insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Aug 19, 2026 | Jennifer Tousignant (C-suite exec) | Sold | $245K |
| Aug 19, 2026 | Jennifer Tousignant (C-suite exec) | Bought (not open market) | $144K |
| Aug 19, 2026 | Jennifer Tousignant (C-suite exec) | Sold | $103K |
| Aug 19, 2026 | Jennifer Tousignant (C-suite exec) | Bought (not open market) | — |
| Aug 14, 2026 | Radhika Tripuraneni (C-suite exec) | Bought (not open market) | $528K |
| Aug 14, 2026 | Radhika Tripuraneni (C-suite exec) | Bought (not open market) | — |
| Jul 1, 2026 | Christopher W. Cain (Insider) | Bought (not open market) | — |
| Jul 1, 2026 | Jeffrey Robert Ajer (Insider) | Bought (not open market) | — |
| Jul 1, 2026 | Jennifer K. Moses (Insider) | Bought (not open market) | — |
| Jul 1, 2026 | Sarah Gheuens (Insider) | Bought (not open market) | — |
| Jul 1, 2026 | Tomas Kiselak (Insider) | Bought (not open market) | — |
| Jul 1, 2026 | Arlene Morris (Insider) | Bought (not open market) | — |
| May 11, 2026 | Fairmount Funds Management LLC (10% owner) | Bought | $20M |
| Mar 3, 2026 | Stephen F. Mahoney (CEO) | Sold (not open market) | $224K |
| Mar 3, 2026 | Stephen F. Mahoney (CEO) | Sold (not open market) | $224K |
| Mar 3, 2026 | Thomas W. Beetham (COO) | Sold (not open market) | $92K |
| Mar 3, 2026 | Thomas W. Beetham (COO) | Sold (not open market) | $92K |
| Mar 3, 2026 | Seth Harmon (CFO) | Sold (not open market) | $61.3K |
| Mar 3, 2026 | Seth Harmon (CFO) | Sold (not open market) | $61.3K |
| Mar 3, 2026 | Jennifer Tousignant (C-suite exec) | Sold (not open market) | $50.6K |
| Mar 3, 2026 | Jennifer Tousignant (C-suite exec) | Sold (not open market) | $50.5K |
| Mar 3, 2026 | Seth Harmon (CFO) | Bought (not open market) | — |
| Mar 3, 2026 | Stephen F. Mahoney (CEO) | Bought (not open market) | — |
| Mar 3, 2026 | Jennifer Tousignant (C-suite exec) | Bought (not open market) | — |
| Mar 3, 2026 | Thomas W. Beetham (COO) | Bought (not open market) | — |
Who's trading VRDN
- Jennifer Tousignant, C-suite exec: sold $419K (3 sales), last Aug 19, 2026
- Radhika Tripuraneni, C-suite exec: other filings, last Aug 14, 2026
- Jeffrey Robert Ajer, Insider: other filings, last Jul 1, 2026
- Christopher W. Cain, Insider: other filings, last Jul 1, 2026
- Sarah Gheuens, Insider: other filings, last Jul 1, 2026
- Tomas Kiselak, Insider: other filings, last Jul 1, 2026
- Arlene Morris, Insider: other filings, last Jul 1, 2026
- Jennifer K. Moses, Insider: other filings, last Jul 1, 2026
- Fairmount Funds Management LLC, 10% owner: bought $30M (2 buys), last May 11, 2026
- Thomas W. Beetham, COO: other filings, last Mar 3, 2026
- Stephen F. Mahoney, CEO: other filings, last Mar 3, 2026
- Seth Harmon, CFO: other filings, last Mar 3, 2026
Get free alerts when an insider at Viridian Therapeutics, Inc.\DE files a new trade →